Sugi Predict

Sugi Predict / Compounds / SCHEMBL2488973

SCHEMBL2488973

SCHEMBL2488973

O=C(Cl)C=Cc1ccccc1[N+](=O)[O-]

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.73
▸ MAOB P27338 1/20 0.67
▸ ALDH1A1 P00352 8/20 0.63
▸ MEN1 O00255 5/20 0.63
▸ KMT2A Q03164 5/20 0.63
▸ RAB9A P51151 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ NFKB1 P19838 1/20 0.61
▸ NFKB2 Q00653 1/20 0.61
▸ RELA Q04206 1/20 0.61
▸ LMNA P02545 3/20 0.60
▸ ATM Q13315 2/20 0.60
▸ HSP90AA1 P07900 1/20 0.60
▸ BACE1 P56817 1/20 0.58
▸ AR P10275 1/20 0.56
▸ POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488970 1.00 MAPT (0.73) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL4185541 0.86 MAPT (0.77) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL4185536 0.86 MAPT (0.77) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL42323 0.84 MAPT (1.00) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL3295983 0.84 MAPT (1.00) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL10673342 0.84 MAPT (1.00) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL820084 0.84 MAPT (1.00) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL1404904 0.83 MAPT (0.73) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL10612875 0.83 MAPT (0.73) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL114330 0.83 MAPT (0.73) MAPTMAOBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0358108-B1 5-(N-3,4,5,6-TETRAHYDROPHTHALIMIDO)-CINNAMIC-ACID DERIVATIVES BASF AG (DE) 1992-04-15 — — EP claimed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 — — CN disclosed
US-8513258-B2 Cinnamoyl-piperazine derivatives and their use as par-1 antagonists PIERRE FABRE MEDICAMENT (FR) 2013-08-20 — — US disclosed
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PEREZ MICHEL (FR) 2012-09-13 — — US disclosed
CN-101472907-B Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists PF MEDICAMENT 2012-08-29 — — CN disclosed
US-8217046-B2 Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists PIERRE FABRE MEDICAMENT (FR) 2012-07-10 — — US disclosed
EP-1756112-B1 PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS BOEHRINGER INGELHEIM INT (DE) 2011-10-26 — — EP disclosed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 — — EP disclosed
US-7727434-B2 Membranes and methods of treating membranes GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7714010-B2 Pyrrolobenzimidazolones and their use as anti-proliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 — — US disclosed
WO-2007147824-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2007-12-27 — — WO disclosed
US-20070039874-A1 Membranes and methods of treating membranes GENERAL ELECTRIC COMPANY 2007-02-22 — — US disclosed
US-20050261350-A1 Pyrrolobenzimidazolones and their use as anti-proliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 — — US disclosed
EP-1598353-A1 Pyrrolobenzimidazolones and their use as antiproliferative agents Boehringer Ingelheim International GmbH (DE) 2005-11-23 — — EP disclosed
US-6689899-B2 HYDROGENATION OF THE CORRESPONDING DINITRO COMPOUNDS KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2004-02-10 — — US disclosed
US-20020019558-A1 Diamine and acid anhydride KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2002-02-14 — — US disclosed
US-6303742-B1 CHARACTERIZED BY A CINNAMOYL GROUP OR A DERIVED CINNAMOYL GROUP INCORPORATED THEREIN AND BY PHOTO-REACTIVITY AND HEAT-REACTIVITY WHICH ARE INHERENT IN THE CINNAMOYL GROUP. KANEKAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2001-10-16 — — US disclosed
US-4883653-A PLASTICS AND COSMETICS, SUNSCREENS OLIN CORPORATION (US) 1989-11-28 — — US disclosed
US-4835312-A Production process of N-substituted amide compounds MITSUI CHEMICALS, INCORPORATED (JP) 1989-05-30 — — US disclosed
US-4350692-A CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232097-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 MAPT 4777/4885MAOB 1737/4885ALDH1A1 1137/4885
US-20050261350-A1 Pyrrolobenzimidazolones and their use as anti-proliferative agents MKI67, CCNI, CCNA1 MAPT 2325/4885MAOB 1736/4885ALDH1A1 618/4885
US-20020019558-A1 Diamine and acid anhydride CA1, ASIC1, CA4 MAPT 573/4885MAOB 1298/4885ALDH1A1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.